Given the effectiveness immunotherapy has shown combined with anti-angiogenic therapy in HCC, numerous clinical trials (outlined in Table 2) aim to explore combination regimens of immunotherapy, CTLA4 inhibitors, and tyrosine kinase inhibitors. Here, CTLA4 is linked to hepatocellular carcinoma.